BULLISHEngages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Shareholders may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus statutory numbers for both revenue and earnings per share increased, with their view clearly much more BULLISH on the company's business prospects. hopefully by the end of the this week there is a possibility to shoot up here!
